Publish in this journal
Journal Information
Vol. 57. Issue 2.
Pages 155-160 (February 2004)
Share
Share
Download PDF
More article options
Vol. 57. Issue 2.
Pages 155-160 (February 2004)
DOI: 10.1016/S1885-5857(06)60104-7
Full text access
Use of the «Minnesota Living With Heart Failure» Quality of Life Questionnaire in Spain
Aplicación en España del cuestionario sobre calidad de vida «Minnesota Living With Heart Failure» para la insuficiencia cardíaca
Visits
...
Teresa Parajóna, Josep Lupóna, Beatriz Gonzáleza, Agustín Urrutiaa, Salvador Altimira, Ramón Colla, Montserrat Pratsa, Vicente Vallea
a Unitat d'Insuficiència Cardíaca. Hospital Universitari Germans Trias i Pujol. Badalona. Barcelona. Spain.
Article information
Statistics
Tables (6)
TABLE 1. Baseline Characteristics
Fig. 1. Medians, 25th and 75th percentiles and extremes values for MLWHFQ scores for each functional class. NYHA indicates New York Heart Association; N, number of patients in each functional class; MLWHFQ, Minnesota Living With Heart Failure Questionnaire.
Fig. 2. Medians, 25th and 75th percentiles and extreme values for MLWHFQ scores for both sexes. N indicates number of patients of each sex; MLWHFQ, Minnesota Living With Heart Failure Questionnaire.
Fig. 3. Medians, 25th and 75th percentiles and extreme values for MLWHFQ scores. A: patients with and without diabetes. B: patients with and without anemia. No. indicates number of patients in each subgroup; MLWHFQ, Minnesota Living With Heart Failure Questionnaire.
Fig. 4. Medians, 25th and 75th percentiles and extreme values for MLWHFQ scores with respect to number of hospitalizations in the previous year. No. indicates number of patients in functional class; MLWHFQ, Minnesota Living With Heart Failure Questionnaire.
Fig. 5. Medians, 25th and 75th percentiles and extreme values for MLWHFQ scores with respect to heart failure etiology: IHD indicates ischemic heart disease; DC, dilated cardiomyopathy; No. number of patients in functional class; HHD, hypertensive heart disease; Al C, alcoholic cardiomyopathy; Tox C, toxic cardiomyopathy (adriamycin); Valv, valve disease.
Show moreShow less
Introduction and objectives. Quality of life is an important end-point in heart failure studies, as well as mortality and hospitalization rates. The Minnesota Living With Heart Failure Questionnaire is the instrument used most widely to evaluate quality of life in research studies. We used this questionnaire to evaluate quality of life in a general population attended by a heart failure unit in Spain. Patients and method. 326 patients seen for the first time at the unit were evaluated. We analyzed the relationship between the questionnaire score and different clinical and demographic factors. Results. The median global score on the Minnesota Living With Heart Failure Questionnaire was relatively low (28). We found a strong correlation (P<.001) between the score and functional class, sex (women had higher scores), and diabetes. We also found a correlation between the score and number of hospital admissions in the previous year (P< .001), anemia (P<.001) and etiology (P=.01), and a weak trend toward higher scores with increasing age (P=.04). The highest scores were observed in patients with valve disease disorders (43), and the lowest were seen in patients with alcoholic cardiomyopathy (20) and ischemic heart disease (24). We found no correlation with time of evolution of heart failure or with left ventricular ejection fraction. Conclusions. The scores on the Minnesota Living With Heart Failure Questionnaire in a general population attended by a heart failure unit in Spain were relatively low. However, we found a strong correlation between this score and functional class, and also between this score and number of admissions in the previous year. These results suggest that the questionnaire adequately reflects the severity of the disease.
Keywords:
Heart failure
Quality of life
Minnesota
Introducción y objetivos. La calidad de vida es, junto con la mortalidad y las hospitalizaciones, un objetivo importante en los estudios sobre insuficiencia cardíaca. El cuestionario «Minnesota Living With Heart Failure» es el instrumento más extensamente utilizado para valorarla en los trabajos de investigación. Nuestro objetivo ha sido conocer la calidad de vida mediante este cuestionario en una población general atendida en una unidad de insuficiencia cardíaca. Pacientes y método. Se evaluó a 326 pacientes en la primera visita. Hemos analizado la correlación entre la puntuación obtenida y diversos factores clínicos y demográficos. Resultados. La puntuación global fue relativamente baja (28). Encontramos una fuerte correlación (p < 0,001) con la clase funcional, el sexo (puntuaciones más altas en mujeres) y la diabetes. Hallamos también correlación con el número de ingresos durante el año previo (p < 0,001), la anemia (p < 0,001) y la etiología (p = 0,01), y una débil tendencia a aumentar con la edad (p = 0,04). Las puntuaciones más altas se observaron en pacientes valvulares (43) y las más bajas en pacientes con cardiopatía alcohólica (20) e isquémica (24). No hallamos correlación con el tiempo de evolución ni con la fracción de eyección de ventrículo izquierdo. Conclusiones. La aplicación del «Minnesota Living With Heart Failure» a una población general con insuficiencia cardíaca ha mostrado puntuaciones relativamente bajas. A pesar de ello, hemos encontrado una correlación importante de la puntuación obtenida con la clase funcional y con el número de ingresos en el año previo, lo que sugiere que el cuestionario refleja correctamente el grado de severidad de la enfermedad.
Palabras clave:
Insuficiencia cardíaca
Calidad de vida
Minnesota
Full text is only aviable in PDF
Bibliography
[1]
McMurray JJ, Stewart S..
Epidemiology, aetiology, and prognosis of heart failure..
Heart, 83 (2000), pp. 596-602
[2]
McCullough P, Philbin E, Speretus J, Kaatz S, Sandberg K, Weawer D..
Confirmation of a heart failure epidemic: findings from the Resource Utilisation Among Congestive Heart Failure (REACH) Study..
J Am Coll Cardiol, 39 (2002), pp. 60-9
[3]
McMurray JJ, Petrie MC, Murdoch DR, Davie AP..
Clinical epidemiology of heart failure: public and private health burden..
Eur Heart J, 19 (1998), pp. 9-12
[4]
Konstam V, Salem D, Pouleur H, Kostis J, Gorkin L, Shumaker S, et al..
Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators..
Am J Cardiol, 78 (1996), pp. 890-5
[5]
Hulsmann M, Berger R, Sturm B, Bojic A, Woloszczuk W, Bergler-Klein J, et al..
Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure..
Eur Heart J, 23 (2002), pp. 886-91
[6]
Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, et al..
Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators..
J Am Coll Cardiol, 23 (1994), pp. 393-400
[7]
Alta F, Briançon S, Guillemin F, Jullière Y, Mertès PM, Villemot JP, et al, for the EPICAL investigators..
Self-rating of quality of live provides additional prognostic information in heart failure. Insights into the EPICAL study..
Eur J Heart Failure, 4 (2002), pp. 337-43
[8]
Guyatt GH..
Measurement of health related quality of life in heart failure..
J Am Coll Cardiol, 22 (1993), pp. 185A-91A
[9]
Rector TS, Kubo SH, Cohn JN..
Patients' self assessment of their congestive heart failure: II. Content, reliability and validity of a new measure-the Minnesota Living with Heart Failure questionnaire..
Heart Failure, 3 (1987), pp. 198-209
[10]
Rector TS, Kubo SH, Cohn JN..
Validity of the Minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo..
Am J Cardiol, 71 (1994), pp. 1106-7
[11]
Rector TS, Cohn JN..
Assessment of patient outcome with the Minnesota Living With Heart Failure questionnaire: reliability and validity during a randomised, double blind, placebo-controlled trial of pimobendan..
Am Heart J, 124 (1992), pp. 1017-25
[12]
Rector TS, Johnson G, Dunkman B, Daniels B, Farrell L, Smith B, et al..
Evaluation by patients with heart failure of effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II..
Circulation, 87 (1993), pp. 71-7
[13]
Kubo S, Gollub S, Bourge R, Rahko P, Cobb F, Jessup M, et al..
Beneficial Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. results of a multicenter trial..
Circulation, 85 (1992), pp. 942-9
[14]
Briançon S, Alla F, Mejat E, Guillemin F, Villemot JP, Mertès PM, et al..
Measurement of functional inability and quality of life in cardiac failure. Transcultural adaptation and validation of the Goldman, Minnesota and Duke questionnaires..
Arch Mal Coeur Vaiss, 90 (1997), pp. 1577-85
[15]
Quittan M, Wiesinger GF, Crevenna R, Nuhr MJ, Posch M, Hülsman M, et al..
Cross-cultural adaptation of the Minnesota Living with Heart failure Questionnaire for german-speaking patients..
J Rehabil Med, 33 (2001), pp. 182-6
[16]
Stanek E, Oates M, McGhan F, Denofrio D, Loh E..
Preferences for treatment outcomes in patients with heart failure: symptoms versus survival..
J Card Failure, 3 (2000), pp. 225-32
[17]
Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW..
Preferences for quality of life or survival expressed by patients with heart failure..
J Heart Lung Transplant, 20 (2001), pp. 1016-24
[18]
Wiklund I, Lindvall K, Swedberg K, Zupkis RV..
Self-assessment of quality of life in severe heart failure..
Scand J Psychol, 28 (1987), pp. 220-5
[19]
Guyatt GH, Nogradi S, Halcrow S, Singer J, Sullivan MJ, Fallen EL..
Development and testing of a new measure of health status for clinical trials in heart failure..
J Gen Intern Med, 4 (1989), pp. 101-7
[20]
Green CP, Porter CB, Bresnahan R, Spertus JA..
Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure..
J Am Coll Cardiol, 35 (2000), pp. 1245-55
[21]
O'Leary C, Jones P..
The left ventricular dysfunction questionnaire (LVD-36): reliability, validity and responsiveness..
Heart, 83 (2000), pp. 634-40
[22]
Feinstein A, Fisher M, Pigeon G..
Changes in dyspnoea-fatigue rating as indicators of quality of life in the treatment of congestive heart failure..
Am J Cardiol, 64 (1989), pp. 50-5
[23]
Riegel B, Moser DK, Glaser D, Carlson B, Deaton C, Armola R, et al..
The Minnesota Living With Heart Failure Questionnaire: sensitivity to differences and responsiveness to intervention intensity in a clinical population..
Nurs Res, 51 (2002), pp. 209-18
[24]
Dracup K, Walden JA, Stevenson LW, Brecht ML..
Quality of life in patients with advanced heart failure..
J Heart Lung Transplant, 11 (1992), pp. 273-9
[25]
Riedinger MS, Dracup KA, Brecht ML, Padilla G, Sarna L, Ganz PA..
Quality of life in patients with heart failure: do gender differences exist?.
Heart Lung, 30 (2001), pp. 105-16
[26]
Evangelista S, Kagawa-Singer M, Dracup K..
Gender differences in health perceptions and meaning in persons living with heart failure..
Heart Lung, 30 (2001), pp. 167-76
[27]
Riegel B, Moser DK, Carlson B, Deaton C, Armola R, Sethares K, et al..
Gender differences in quality of life are minimal in patients with heart failure..
J Cardiac Failure, 9 (2003), pp. 42-8
[28]
Lader E, Egan D, Hunsberger S, Garg R, Czajkowski S, McSherry..
The effect of digoxin on the quality of life in patients with heart failure..
J Cardiac Failure, 9 (2003), pp. 4-12
[29]
Kukin M, Kalman J, Charney RH, Levy DK Buchholz-Varley C, Ocampo OF, et al..
Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure..
Circulation, 99 (1999), pp. 2645-51
[30]
Reddy P, Dunn AB..
The effect of beta-blokers on health-related quality of life in patients with heart failure..
Pharmacotherapy, 20 (2000), pp. 679-89
[31]
Hutcheon SD, Gillespie ND, Crombie IK, Struthers AD, McMurdo MET..
Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial..
Heart, 88 (2002), pp. 373-7
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?